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Surgical Treatment of 
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Francesca Nicolo’, Antonio Lio, Marina Comisso, 
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Abstract
Hypertrophic cardiomyopathy is a genetic disorder of the myocardium, char-
acterized by marked myocardial hypertrophy that may lead to the development of 
symptoms such as dyspnea, angina pectoris, or stress-induced syncopes, with an 
increased risk of sudden cardiac death, due to obstruction of the left ventricular 
outflow tract (hypertrophic obstructive cardiomyopathy). Septal reduction treat-
ment is needed in these patients, in order to relieve of the symptoms. In addition, 
mitral valve apparatus should be assessed in these patients, in order to recognize a 
dynamic movement of the MV during systole anteriorly toward the LVOT. In this 
chapter, we will describe the current surgical management of HOCM.
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1. Introduction
Hypertrophic cardiomyopathy (HCM) is a genetic disorder of the myocar-
dium, characterized by marked myocardial hypertrophy (>15 mm) that cannot 
be explained by any other diseases that may cause secondary hypertrophy [1]. Its 
prevalence is 0.2–0.6% [2], with an overall annual mortality rate of 1%.
People with HCM often remain oligosymptomatic or even asymptomatic for 
many years; anyway, they may develop as cardinal symptoms dyspnea, angina pec-
toris, or stress-induced syncopes, with an increased risk of sudden cardiac death, 
particularly in young people and athletes [3], due to obstruction of the left ven-
tricular outflow tract (LVOT). This obstruction is dynamic and largely influenced 
by changes in left ventricular loading and contractility, with subsequently increased 
left ventricular systolic pressure and secondary mitral regurgitation (MR), myo-
cardial ischemia, and reduction in cardiac output. Around 70% of patients with 
HCM display relevant obstruction (HOCM) with a high peak pressure difference 
(more than 30 mm Hg) [4]; in half of these patients the obstruction is present even 
at rest, while in the remainder it is latent, so that a gradient can be demonstrated 
only under stress. Septal reduction treatments can lead to considerable relief of the 
symptoms even in patients whose obstruction is latent.
Echocardiography is an important and reliable method for diagnosing HOCM 
and for planning the kind of treatment. Echocardiography enables determina-
tion of the extent of the left ventricular hypertrophy and of the site, severity, and 
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mechanism of any obstruction. In addition, mitral valve (MV) apparatus can be 
adequately studied, in order to recognize any systolic distortion of the MV associated 
with systolic anterior motion (SAM) that often leads to secondary MR (Figure 1).
Despite medical therapy (treatment with B-blockers or, sometimes, Verapamil) 
is the first-line therapy for symptomatic patients with LVOT obstruction [1], a large 
proportion of patients with dynamic obstruction remain symptomatic so, a septal 
reduction treatment (SRT) is needed in order to relief of the symptoms. This can 
take the form of either septal myectomy or percutaneous alcohol ablation of the sep-
tum [5]. In this chapter we will describe the current surgical management of HOCM.
2. Anatomical classification of HCM
Morphology is variable, common variants being basal, mid-ventricular, apical, 
and diffuse types have been described. Maron classification reported 4 variants of 
HCM [6]:
• Type 1: hypertrophy (10% of patients) confined to the anterior portion of the 
ventricular septum;
• Type 2: hypertrophy (20% of patients), involves the anterior and posterior 
portion of the ventricular septum;
• Type 3: hypertrophy (52% of patients), involves the anterior and posterior 
portion of the ventricular septum as well as the lateral free wall;
• Type 4: hypertrophy (18% of patients), involves left ventricular regions other 
than the anterior septum and the posterior free wall.
Figure 1. 
Transthoracic echocardiography showing LVOT obstruction (A), with a resting LVOT gradient of 77 mmHg 
(B) and severe MR, due to SAM (C). Figure courtesy of non-invasive cardiology diagnostic laboratory, 
Cardiology Department, L. Sacco Hospital, Via G.B. Grassi 74, Milano, Italy.
3Surgical Treatment of Hypertrophic Obstructive Cardiomyopathy
DOI: http://dx.doi.org/10.5772/intechopen.86816
3. Surgical indication
ACC/AHA and ESC guidelines recommend that septal reduction therapy should 
be performed only by experienced operators, working as part of a multidisciplinary 
team expert, in the management of HCM [1, 7]. A SRT should be performed in 
presence of:
1. Significant LVOT obstruction (resting or maximum provoked LVOT gradient 
of ≥50 mmHg)
2. Angina, Dyspnea (NYHA functional class III-IV), Syncope
3. Persistent symptoms on maximal medical therapy.
4. The current indications have expanded recently to include symptomatic 
patients with low resting outflow gradients and latent obstruction.
4. Surgical approaches
1. Standard median sternotomy
2. Ministernotomy
3. Right anterolateral minithoracotomy (IV I.S.)
5. Surgical septal myectomy
Surgical septal myectomy is the therapeutic gold standard for the treatment of 
drug-refractory disabling symptoms in HCM caused by LVOT obstruction. This 
procedure can relieve hemodynamic disorders and has an acceptable surgical risk 
when performed on appropriate patients and in experienced centers [7].
It was performed, for the first time, in 1968 by Morrow et al. [8]; initially, 
the myectomy was limited in scope, but nowadays the resection is much more 
aggressive in terms of both width and length [5, 9]. Sparing the cardiac conduc-
tion system, septal myocardium is resected, depending on the area of hypertrophy 
and extending if necessary as far as the level of the papillary muscles, to an extent 
sufficient to eliminate the obstruction, retaining septal thickness of 1 cm. Surgical 
septal myectomy can be performed as follows:
5.1 Transaortic extended septal myectomy (TAESM)
TAESM through a transverse aortotomy, the aortic valve is totally exposed and 
the aortic leaflets are retracted so as to inspect the LVOT, the hypertrophic cardiac 
muscle and anterior MV leaflet. In order to open the LVOT and reduce the gradient 
to <30 mmHg, resection of the hypertrophic muscle until the thickness of the LV 
wall and interventricular septum became nearly normal by visual inspection, has 
to be performed. The myectomy should be initiated about 1.5 cm below the aortic 
annulus starting at the level of the non-coronary/right-coronary commissure to 
avoid the membranous septum and avoid creating a secondary ventricular septal 
defect (VSD). The septum is cut into as much as possible to relieve the obstruction 
and it is extended toward the left/non-coronary commissure so that the entire 
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septum is trimmed off all around (Figure 2). The TAESM is the most commonly 
used technique and it has been associated with very low mortality, consistent 
alleviation of outflow gradients and excellent long-term survival [10].
5.2 Transmitral septal myectomy (TMSM)
The MV is approached through the left atrium, in the interatrial groove. Then, 
the base of the AL is widely detached from commissure to commissure, with the 
septum that lies just in front of the surgeon. The myectomy is continued further 
toward the apex with at least 1 cm depth of muscle removed. The anterior MV 
leaflet is then reconstructed (sometimes using an autologous pericardial patch 
with the size of the patch that should be as biggest as possible, in order to move 
posteriorly toward the left ventricle the coaptation plane). This approach is useful 
for those patients with diffuse hypertrophy extending to or below the papillary 
muscles with midcavity muscular obstruction: these patients are suboptimal can-
didates for the Morrow procedure. Benefits of the transmitral exposure include 
a wide view of the ventricular septum, absent risk of injury to the aortic valve 
cusps, and the opportunity to address concomitant abnormalities of the MV and 
subvalvular apparatus.
5.3 Complete septal myectomy by a double approach (aortic and mitral)
In patients with simultaneous MR due to SAM, the insufficiency is almost always 
reduced or eliminated by myectomy alone. Sometimes, there may be associated a 
lesion of the aortic valve and/or fibrous subaortic stenosis; these also require surgi-
cal correction, depending on their severity. Intraoperative echocardiography helps 
the surgeon to determine the individual extent of the disease and decide on the 
necessary scope of resection.
Figure 2. 
Extension of the resection under the membranous septum.
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More difficult to treat are patients with an apical variant of HCM; they have 
obliteration of the left ventricular chamber with severe diastolic dysfunction. The 
results of myectomy depend essentially on the experience and competence of the 
surgeon. Only in specialized centers can myectomy be carried out with a risk of 
perioperative complications under 1%. The hemodynamic results are usually excel-
lent with a postoperative gradient <10 mm Hg [11]. VSD, atrioventricular block and 
residual obstruction may complicate a septal myotomy; anyway, incidence is lower 
for experienced surgeons with a risk <3% in expert hands [12]. Long-term results 
following surgery are good, with more than 90% of patients being asymptomatic 
[13]. Septal myectomy is the gold standard in SRT, because of fewer complications 
and better freedom from redo procedures, with a better long term outcome rather 
than septal ablation.
6. Adjuncts to septal myectomy
6.1 SAM correction
SAM describes the dynamic movement of the MV during systole anteriorly 
toward the LVOT. It occurs in 31–61% of HCM patients, and it is associated with 
resting LVOT obstruction in 25–50% of them [14].
SAM-mediated MR typically resolves with extended myectomy alone, 
anyway, a well comprehension of all the mechanisms that can predispose to or 
precipitate SAM, is important, in order to treat this mechanism. Factors predis-
posing to SAM are:
a. structural anomalies such as:
• small left ventricular chamber
• bulging septum
• chordal anomaly
• papillary muscle displacement
• redundant anterior or posterior leaflets
b. geometric factors such as:
• annular undersizing
• anterior displacement of MV (any anatomical or surgical translocation of the 
MV anteriorly will increase the forces acting to draw the MV anteriorly that 
may precipitate SAM)
• low anterior—posterior (A-P) length ratio (A-P leaflet length ratio <1.3 is a 
risk factor for SAM)
• reduced mitral-aortic angle (<15°)
• distance reduction between MV coaptation point and septum
Cardiac Surgery Procedures
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Figure 4. 
Quadrangular P2 resection + sliding plasty. Adapted from the book “Reconstructive Valve Surgery”, by 
Carpentier et al. 2010, Imprint: Saunders, Copyright: © Saunders 2010.
c. kinetic factors such as
• hyperdynamic left ventricle (LV)
Surgical techniques proposed to correct concomitant SAM in HOCM are:
• Changes to posterior leaflet height, in order to avoid anterior shifting of the 
coaptation point closer to the base of the anterior leaflet, which predispose to 
SAM [15]. The resulting posterior mitral leaflet (PML) should have a reduced 
height of 1 cm:
 ○ triangular resection of PML and ventricularization [16];
 ○ sliding posterior leaflet plasty technique (moves the coaptation point poste-
riorly) [17] (Figures 3–5);
 ○ modified sliding leaflet technique (middle scallop of PML is resected, dif-
fers from Carpentier in eliminating triangular resection) [18] (Figure 6);
Figure 3. 
Quadrangular P2 resection. Adapted from the book “Reconstructive Valve Surgery”, by Carpentier et al. 2010, 
Imprint: Saunders, Copyright: © Saunders 2010.
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 ○ PML folding plasty [19];
 ○ Loop technique (height adjustment of the mitral leaflets using artificial chor-
dae: after artificial chordae and annuloplasty ring placement in the normal 
way, a polyester reduction suture with a spaghetti loop supporting it is placed 
on the posterior leaflet surface, and tied down until its height is <1.5 cm), 
[20] (Figure 7);
 ○ chordal translocation (PML secondary chordae are transected and moved to 
the AML) [21];
 ○ edge-to-edge, or Alfieri stitch technique (A1-P1 stitch instead of  
midline) [22].
• Changes to anterior leaflet height, in order to reduce the redundant leaflet and, 
subsequently, the A-P length ratio (risk factor for SAM development):
Figure 5. 
Final result of quadrangular P2 resection + sliding plasty. Adapted from the book “Reconstructive Valve 
Surgery”, by Carpentier et al. 2010, Imprint: Saunders, Copyright: © Saunders 2010.
Figure 6. 
Posterior mitral valve leaflet shortening.
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 ○ elliptical excision of the anterior mitral leaflet (excision site is then closed 
with double-layer prolene stitches) [23];
 ○ elliptical excision with repositioning of major basal chords [24];
 ○ removal of accessory chordae that may tether the AML to the septum, 
resulting in SAM [25].
• Annuloplasty ring sizes: any reduction in annular circumference reduces the 
mitral—aortic angle, which increases the risk of SAM, so an annular under-
sizing should not be performed, in order to maintain the coaptation plane as 
much as possible away from the septum:
 ○ annular enlargement (post-MV repair, especially in Barlow’s disease): 
36–40 mm annular rings are used in presence of excessive mitral tissue [26];
 ○ annular plication: plication sutures are used to tie down the PML to the 
annulus [27];
• “Resection-plication-release”: in HCM, the concomitant use of myectomy, plica-
tion of the AML and release of the papillary muscles remodels the LV in order 
to reduce SAM [28].
• Mitral valve replacement: if SAM is severe and persistent despite exhaustive 
medical and surgical attempts at eliminating SAM, MV replacement can be the 
only option. In this setting, care must be taken to properly resect any remain-
ing mitral tissue, to prevent SAM recurring.
6.2 Arrhythmia surgery
Patients with HCM are at increased risk of development of atrial fibrilla-
tion due to long-standing elevation of the left ventricular end-diastolic and left 
atrial pressures with subsequent left atrial chamber enlargement. Anyway, there 
is little evidence to support the addition of the Cox-maze procedure to septal 
myectomy.
Figure 7. 
Loop technique.
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6.3 Management of papillary muscle abnormalities
Sometimes, LVOT obstruction is present after septal myectomy because of 
anomalies of the (MV) valve apparatus: an accessory papillary muscle that arises from 
the ventricular septum and that is attached to the side of the anterior leaflet, may be 
present. In these patients, the accessory muscle has to be excised in its entirety. Other 
anomalies of the mitral apparatus may be the presence of accessory papillary muscles, 
or fusion of the anterior papillary muscle with the ventricular septum or left-ventricular 
free wall, or the presence of abnormal chordae tendineae that attach to the ventricular 
septum or to the free wall; all of this abnormalities may contribute to a persistent LVOT 
gradient and should be corrected in order to perform an adequate SRT.
In HCM, the anterior and inward displacement of papillary muscles is thought to 
create diastolic downwards vortex forces which pull the MV into the LVOT [29].
6.4 Management of concomitant MV disease
Degenerative MV disease requires attention at the time of myectomy in contrast 
to SAM-mediated MR that typically resolves with extended myectomy alone.
In our experience, when a concomitant mitral valve repair (MVR) is needed, we 
use a flexible posterior band that is slightly upsized, in order to minimize or avoid 
potential development of SAM postoperatively.
7. Other indications for septal myectomy
Apical and midventricular variants of HCM are difficult entities to diagnose and 
treat medically, with the only alternative to myectomy being heart transplantation.
8. Septal myectomy versus alcohol septal ablation
Despite an extended surgical septal myectomy is considered the gold standard 
for managing symptomatic patients [1], percutaneous alcohol ablation of the 
septum has emerged as an alternative to surgical septal myectomy [30]. In this 
approach, alcohol is injected into the first septal perforator in order to create a 
localized myocardial infarction. The advantages of this non surgical procedures 
are a faster recovery with a subsequent quick return to daily lifestyle; anyway, the 
literature tends to support better long-term symptom relief in those patients who 
undergo septal myectomy [31] with a higher procedural success and a lower rate of 
complications when myectomy is performed in experienced centers compared with 
alcohol septal ablation. In addition, we have to keep in mind that young patients and 
patients with severe or relatively thin septal thickness and a very high LVOT gradi-
ent are considered poor candidates for the percutaneous approach. Importantly, 
surgical septal myectomy also facilitates the correction of other abnormalities of the 
LVOT and repair of associated abnormalities of the MV and anomalous papillary 
muscles that can also contribute to residual dynamic outflow tract obstruction.
9. Conclusions
Due to the complex ventricular phenotype of septal hypertrophy which 
increases the drag forces acting on the MV, and also due to primary MV anomalies, 
a multifaceted approach to repair and abolition of LVOT obstruction is required 
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in HOCM. Septal myectomy is fundamental and represent the first step to any 
of these. In addition, specific techniques for SAM in the context of HOCM have 
been described. Each technique proposed for the surgical correction of HOCM has 
evolved to meet a specific anatomical problem, so it is inappropriate to rate one sur-
gical procedure as superior to another; anyway, repair which resects as little tissue 
as possible and that does not distort the anatomy significantly should be preferred. 
Surgeons must understand the anatomical cause of LVOT obstruction, and this 
should guide them to the choice of the technique to adopt. Ease of repair should be 
also considered, as this will have beneficial consequences for the total time under 
cardiopulmonary bypass.
Alcohol septal ablation for HCM has been proposed as a less-invasive alternative 
to surgical myectomy, although its role in the management of HCM associated with 
SAM requires further investigations so that, the current evidence, supports the use 
of septal myectomy in the clinical practice [32].
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